Today’s most trending tickers with positive sentiment (last 24h):

$SPY: 22
$SPX: 11
$DVLT: 8
$VIX: 7
$ASTS: 7
$PANW: 6
$VVOS: 5
$VOO: 4
$NVDA: 4
$ARTL: 4
$AAPL: 4
$ASTC: 4
$USO: 4

Today’s most trending tickers with positive sentiment (last 24h):

$SPY: 41
$META: 16
$VIX: 14
$ARTL: 13
$RCKT: 11
$SPX: 10
$NXXT: 9
$NVDA: 9
$VVOS: 7
$MSFT: 7
$ASTS: 6
$NBIS: 6
$NFLX: 6
$MU: 5
$VSA: 5
$IPO: 4
$BTC: 4
$DHS: 4

$VVOS reaches new intraday high after positive cash flow and in-network status, setting up for further gains.

Today’s most trending tickers with positive sentiment (last 24h):

$SPY: 18
$META: 16
$UGRO: 14
$TSLA: 12
$MSFT: 11
$IPO: 9
$SPX: 8
$VIX: 7
$AIFF: 7
$ARM: 6
$AAPL: 6
$AMZN: 6
$NFLX: 6
$MU: 6
$NXXT: 5
$ASTS: 5
$VVOS: 5
$USEG: 5

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy Vivos Therapeutics (NASDAQ: VVOS) highlighted a peer-reviewed study linking narrower maxillary intermolar distance and higher palatal height to greater obstructive sleep apnea (OSA) severity, reporting a strong association (p<0.001) across 100 patients.The company noted its FDA 510(k) clearance in November 2024 for Vivos CARE devices to treat severe OSA, U.S. clearance for adults and children, and asserted many patients finish treatment in under 12 months, often reducing the need for nightly CPAP or other lifetime interventions.

#VVOS Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

www.stocktitan.net/news/VVOS/recent-study-c...

#VVOS sees significant buying activity today after Vivos reports increased Vanguard Group position.

#VVOS sees big buy orders after reporting significant increase in Vanguard Group's position, trading at low Price-to-Sales ratio

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds Vivos Therapeutics (Nasdaq: VVOS) announced a definitive agreement for immediate exercise of outstanding warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, down from original prices of $3.83–$5.05. The shares issuable upon exercise are registered for resale on Form S-3. Gross proceeds to the company are expected to be approximately $4.64 million before placement agent fees and offering expenses. The company will issue private, unregistered new warrants to purchase up to 3,964,712 shares at $2.09 per share; portions expire in 24 months and five years. The offering is expected to close on or about January 20, 2026, and net proceeds will be used for working capital and general corporate purposes.

#VVOS Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

www.stocktitan.net/news/VVOS/vivos-therapeu...

Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan Vivos Therapeutics (NASDAQ: VVOS) opened an affiliated sleep testing and treatment center in Auburn Hills, Michigan on Dec. 16, 2025, expanding its commercial affiliation model beyond Las Vegas.The center operates under a July agreement with MISleep Solutions, where Vivos built out the facility, staffed and trained personnel, and will provide its FDA-cleared diagnostic and therapeutic products for obstructive sleep apnea (OSA). Vivos positions the affiliation model as capital-efficient versus outright acquisitions while preserving accretive economics and expects to pursue similar partnerships nationwide.

#VVOS Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

www.stocktitan.net/news/VVOS/vivos-therapeu...

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19,

#VVOS Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

www.stocktitan.net/news/VVOS/vivos-therapeu...

Trade Alerts, Tuesday November 4, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend, average directional index, Tue Nov 4th - #VVOS #CCOI #FLD #GAMB #ICHR #NNNN #PHUN #SLE #TELA #UEIC #VIRC #UP #WERN #SAFE #RWT #PSFE #ODC #NGVC #LOB #HSHP #FBRT #CHGG #CHNG #BNED - More: crystalequityresearch.com/trade-alerts... - #smallcap

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device Vivos Therapeutics (NASDAQ:VVOS) has released new clinical data demonstrating significant improvements in children with ADHD and OSA using their FDA-cleared Daytime-Nighttime Appliance (DNA). The study showed remarkable results, including a 50% decrease in pediatric sleep issues and a 58% decrease in ADHD symptoms.The clinical trial, involving 48 children with an average age of 10.6 years, demonstrated 100% of patients experienced increased transpalatal width (+13.6%) and airway volume (+40%), while OSA severity decreased by 51.4%. The DNA appliance represents the only FDA-cleared non-surgical, non-pharmaceutical treatment for moderate to severe pediatric OSA in children ages 6-17.The majority of improvements occurred within the first six months of treatment, offering a promising alternative to traditional adenotonsillectomy surgery and pharmaceutical interventions.

#VVOS Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

www.stocktitan.net/news/VVOS/vivos-therapeu...

77% Success Rate: Vivos' Non-Surgical Device Transforms Sleep Apnea Treatment for Millions of Children Clinical trial shows Vivos DNA appliance reduces OSA severity by 50%+ in 77% of children, with 93% success in severe cases. Alternative to surgery increases airway volume 67.8%.

#VVOS Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

www.stocktitan.net/news/VVOS/vivos-therapeu...

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update Vivos Therapeutics (NASDAQ:VVOS), a medical device company focused on sleep-related breathing disorders, reported Q2 2025 financial results marked by a strategic pivot in their business model. The company completed the acquisition of The Sleep Center of Nevada (SCN), generating approximately $500,000 in diagnostic sleep testing revenue in just 20 days.Q2 2025 financial highlights include revenue of $3.8 million (down from $4.1M in Q2 2024), gross profit of $2.1 million with a 55% margin, and increased operating expenses of $7.0 million. The company ended the quarter with $4.4 million in cash. Additionally, Vivos entered into its first management agreement with MISleep Solutions LLC in Michigan, demonstrating progress in their updated sleep practice management model.

#VVOS Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/VVOS/vivos-therapeu...

Vivos Therapeutics Adds to Management Team to Support Expansion and Growth Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on treating obstructive sleep apnea (OSA), has announced two strategic executive appointments to support its expansion plans. Michael E. Bruhn joins as Executive Vice President of Business Operations Integration, while Dr. Terry Jones becomes Senior Vice President of Human Resources.Bruhn, formerly EVP and COO at the United States Institute of Peace, will focus on expanding Vivos' operations in the Eastern United States and managing acquisitions integration, including the recent Sleep Center of Nevada acquisition. Dr. Jones, with over 20 years of leadership experience across federal agencies and private sector, will lead human resources strategy to support the company's growth phase.Both executives will report directly to CEO R. Kirk Huntsman as Vivos implements its new business model focused on sleep testing centers and direct patient treatment operations.

#VVOS Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

www.stocktitan.net/news/VVOS/vivos-therapeu...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jul 1st - #WETO #ATAI #YYAS #VVOS #VLRS #RUN #RXRX #PL #MNDJF #MDAI #LEU #EOSE #CYN #APLD #BTCS #AEVA #BMNR #ACHC #BGLC - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping up in trading Tue Jul 1st - #BGLC #VVOS #MESO #IGMS #CLRO #ATAI #WOLF #HUYA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

A cozy bed floats among clouds under a starry night sky with a crescent moon, symbolizing restful sleep. Vivos Therapeutics.

#VVOS just scored Medicare approval for its VidaSleep™ oral appliance, unlocking access for millions battling sleep apnea. With two Medicare-covered solutions now on the market, Vivos is reshaping how OSA is treated—no CPAP required.
#VivosTherapeutics
prismmarketview.com/selling-swee...

Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance Vivos Therapeutics (NASDAQ: VVOS) has achieved a significant milestone as its VidaSleep™ oral appliance received approval from the Centers for Medicare & Medicaid Services (CMS) for treating mild to moderate obstructive sleep apnea (OSA) and snoring in adults.The VidaSleep™ device, featuring Vivos' patented and FDA-cleared Unilateral Bite Block technology, joins the company's mmRNA® device on the PDAC list of covered oral appliances. This dual-PDAC approval makes Vivos the only company with two Medicare-covered oral appliances, expanding access to millions of Medicare beneficiaries.With an estimated 80 million Americans affected by OSA and over 80% of cases undiagnosed, Vivos is targeting the $36 billion sleep therapy market. The VidaSleep™ device is designed to offer a cost-effective solution without compromising efficacy, maintaining strong gross margins while expanding accessibility through Medicare and commercial insurance networks.

#VVOS Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance

www.stocktitan.net/news/VVOS/vivos-therapeu...

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children Vivos Therapeutics (NASDAQ: VVOS) announced the publication of groundbreaking clinical trial results in the European Journal of Pediatrics, demonstrating the effectiveness of their Daytime-Nighttime Appliance (DNA) in treating pediatric obstructive sleep apnea (OSA). The study showed 79% of patients experienced OSA improvement, with 61.7% improving by 50% or more.The trial results validate Vivos' FDA 510(k) clearance received in September 2024 for treating moderate to severe OSA in children. Notably, 93% of children with severe OSA saw symptoms decrease by at least 50%. The DNA device presents a non-surgical alternative to adenotonsillectomy, which has a 68% symptom relapse rate within three years.

#VVOS New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

www.stocktitan.net/news/VVOS/new-clinical-t...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend in Average Directional Index, Mon Jun 23rd - #INLF #GNLX #DWTX #VVOS #RFIL #PXLM #OLPX #NN #IMDX #CCNE #BASE #TXO #TEN #SQNS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

#VVOS completes acquisition of Nevada’s largest sleep center, expanding access to its FDA-cleared OSA treatments. The deal supports a new model focused on higher-margin diagnostic and therapeutic revenues.
#VivosTherapeutics
prismmarketview.com/vivos-comple...

Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada Vivos Therapeutics (NASDAQ: VVOS) has completed the acquisition of The Sleep Center of Nevada (SCN), marking a significant pivot in its business model. The $6M cash and $1.5M stock deal includes potential additional $1.5M in stock based on performance milestones. SCN, Nevada's largest sleep testing center, sees 3,000 new patients monthly and generates high seven-figure annual revenues. The acquisition was financed through an $8.225M secured loan from Streeterville Capital and a $3.755M private placement from New Seneca Partners. This strategic move shifts Vivos from a dental provider network model to directly managing sleep practices, allowing immediate capture of OSA diagnostic revenue and treatment opportunities. SCN's network of seven locations and 50 beds for sleep testing, led by Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, will now offer Vivos' FDA-cleared OSA treatments to patients, with full integration expected over 12-18 months.

#VVOS Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

www.stocktitan.net/news/VVOS/vivos-therapeu...

Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update Vivos Therapeutics (NASDAQ: VVOS) reported its Q1 2025 financial results, showing mixed performance as the company transitions to a new business model. Total revenue decreased to $3.0 million from $3.4 million in Q1 2024, though product revenue increased 8% year-over-year. The company reported a net loss of $3.9 million, slightly higher than the $3.8 million loss in Q1 2024. Operating expenses decreased 5% to $5.4 million, reflecting cost-cutting measures. Notably, Vivos announced plans to acquire The Sleep Center of Nevada for up to $9 million, marking a strategic shift towards direct patient access. The company sold 3,736 oral appliance arches in Q1 2025, generating approximately $1.8 million in revenue. Implementation of new CPT® medical codes for CARE oral medical devices aims to improve reimbursement processes.

#VVOS Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/VVOS/vivos-therapeu...

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada Vivos Therapeutics (NASDAQ: VVOS) has signed a definitive agreement to acquire The Sleep Center of Nevada (SCN), the largest sleep center operator in Nevada, for up to $9 million. The deal includes $6 million in cash, $1.5 million in Vivos common stock at closing, and potential additional $1.5 million in stock tied to performance milestones.SCN, founded in 2008, serves approximately 3,000 new patients monthly and has generated high seven-figure annual net revenues. The center operates seven locations with nearly 50 beds for overnight sleep testing. About 90% of SCN patients test positive for OSA, with 95% typically referred for CPAP, traditional oral devices, or surgical options.The acquisition, expected to close in Q2 or Q3 2025, aligns with Vivos' new marketing and distribution model following its June 2024 alliance with Rebis Health. The company aims to expand its FDA-cleared oral appliance treatments for OSA directly to patients seeking alternatives to CPAP or surgery.

#VVOS Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

www.stocktitan.net/news/VVOS/vivos-therapeu...

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update Vivos Therapeutics (NASDAQ: VVOS) reported strong financial results for full year 2024, with revenue increasing 9% to $15.0 million from $13.8 million in 2023. Product revenue grew 26% year-over-year, while operating expenses decreased 21% to $20.2 million.The company maintained a 60% gross margin, with gross profit reaching $9.0 million. Operating loss decreased significantly by 35% to $11.2 million. Cash position stood at $6.3 million after raising $17.9 million through equity transactions in 2024.Notable achievements include FDA 510(k) clearance for the DNA appliance to treat moderate to severe OSA in children ages 6-17, complementing their 2023 clearance for adult treatment. Patient treatments increased to 58,000 worldwide, up from 42,000 in 2023. The company implemented a strategic pivot towards contractual, profit-sharing alliances with sleep healthcare providers, starting with Rebis Health Holdings, expecting to increase revenue per case by 4-6 times with 50% contribution margins.

#VVOS Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

www.stocktitan.net/news/VVOS/vivos-therapeu...

Medical Device Innovator Vivos Sets Key Earnings Date: What to Watch in 2024 Results Sleep disorder treatment innovator Vivos announces FY2024 earnings release and investor call on March 31. Get detailed financial insights and business updates.

#VVOS Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

www.stocktitan.net/news/VVOS/vivos-therapeu...

This Sleep Apnea Treatment is Outperforming CPAP 2-to-1 - Can Vivos Transform Sleep Medicine? Vivos expands FDA-cleared OSA treatment with 64% patient acceptance and 70% margins. New facilities and nationwide sleep center partnerships signal aggressive growth strategy.

#VVOS Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide

www.stocktitan.net/news/VVOS/vivos-therapeu...